Virtual PREHAB Study for Patients Undergoing TAVI

August 19, 2024 updated by: Nova Scotia Health Authority

Feasibility of a Virtually Delivered Preoperative Rehabilitation Program for Patients Awaiting TAVI to Reduce Frailty: The Virtual PREHAB Study

Nova Scotians are aging and many are becoming frailer. People with frailty are more likely to live in worse health and do not recover well from major events, such as open heart surgery. Many people are also too frail to receive open heart surgery. Less invasive procedures called transcatheter aortic valve implantation, or TAVI, are provided for the frailest patients. While TAVI is life-saving, frailer patients are less likely to survive in better health after their operation. Patients in Nova Scotia can also wait up to 3-6 months for their operation where they become frailer or can die before receiving TAVI. The investigators believe that it is important to support these individuals to improve their frailty and overall health before their operation.

Center-based cardiac rehabilitation is offered to patients after, but not before TAVI to improve their health. Center-based preoperative cardiac rehabilitation (i.e., PREHAB) can safely improve the function of frail patients who received open heart surgery. However, many patients cannot come to a center-based PREHAB because of transportation requirements to access the program. Another option is to support these patients with virtually delivered PREHAB, where they can stay in their homes. However, this possibility has not been studied.

For this study, virtual PREHAB will be delivered using the virtual cardiac rehabilitation program in Nova Scotia to patients before TAVI. This intervention will be delivered by healthcare providers who routinely care for TAVI patients, including a medical director, program lead, nurse, physiotherapist, and dietician. Ther goal of this study is to determine if it is feasible and safe to use virtual PREHAB to reduce frailty before TAVI. This research fits with Research Nova Scotia's priorities to improve patient outcomes in those with significant long-term health conditions, and to provide accessible, safe, and quality virtual healthcare to patients so they can thrive after their operation.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B4E 0H4
        • Recruiting
        • Nova Scotia Health
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

46 years to 96 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Outpatients attending the TAVI clinic at the Queen Elizabeth II Health Sciences Centre
  • Informed written or verbal consent

Exclusion Criteria:

  • New York Heart Association or Canadian Cardiovascular Score of 4
  • Severe functional limitations
  • Cognitive impairment that impacts consenting ability
  • Significant language barrier
  • No internet or telephone access that precludes virtual PREHAB participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard Care
In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
Experimental: Virtual PREHAB
In addition to standard care, participants randomized to the The virtual PREHAB program will be delivered by the Hearts and Health in Motion cardiac rehabilitation CR health care team including a medical director nurse, dietician, and physiotherapist who routinely deliver CR postoperatively. The virtual PREHAB program will be up to 8-weeks in duration and deliver the core components of CR online or by telephone.
The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CLSA-FI
Time Frame: Baseline
Canadian Longitudinal Study on Aging Frailty Index; range 0-1 (lower is better)
Baseline
CLSA-FI
Time Frame: 8-weeks preoperatively
Canadian Longitudinal Study on Aging Frailty Index; range 0-1 (lower is better)
8-weeks preoperatively
CLSA-FI
Time Frame: 1-week preoperatively
Canadian Longitudinal Study on Aging Frailty Index; range 0-1 (lower is better)
1-week preoperatively
CLSA-FI
Time Frame: 3-months postoperatively
Canadian Longitudinal Study on Aging Frailty Index; range 0-1 (lower is better)
3-months postoperatively
PFFS-FI
Time Frame: Baseline
Pictorial-Fit Frail Scale Frailty Index; range 0-1 (lower is better)
Baseline
PFFS-FI
Time Frame: 1-week preoperatively
Pictorial-Fit Frail Scale Frailty Index; range 0-1 (lower is better)
1-week preoperatively
PFFS-FI
Time Frame: 8-weeks preoperatively
Pictorial-Fit Frail Scale Frailty Index; range 0-1 (lower is better)
8-weeks preoperatively
PFFS-FI
Time Frame: 3-months postoperatively
Pictorial-Fit Frail Scale Frailty Index; range 0-1 (lower is better)
3-months postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
EQ-5D-5L health-related quality of life
Time Frame: Baseline
Euroqol-5 dimension-5 level health-related quality of life; range 5-25 (lower is better)
Baseline
EQ-5D-5L health-related quality of life
Time Frame: 8-weeks preoperatively
Euroqol-5 dimension-5 level health-related quality of life; range 5-25 (lower is better)
8-weeks preoperatively
EQ-5D-5L health-related quality of life
Time Frame: 1-week preoperatively
Euroqol-5 dimension-5 level health-related quality of life; range 5-25 (lower is better)
1-week preoperatively
EQ-5D-5L health-related quality of life
Time Frame: 3-months postoperatively
Euroqol-5 dimension-5 level health-related quality of life; range 5-25 (lower is better)
3-months postoperatively
VARC-3 Composite clinical end-points
Time Frame: Hospital discharge (assessed up to day 14)
Valvular Academic Research Consortium V.3.0 clinical endpoints (Mortality, Neurologic events, Hospitalization, Rehospitalization, Bleeding and transfusions, Vascular and access-related complications, Cardiac structural complications, Other procedural or valve-related complications, New conduction disturbances and arrhythmias, New conduction disturbances and arrhythmias, Myocardial infarction, Bioprosthetic valve dysfunction, Leaflet thickening and reduced motion, Clinically significant valve thrombosis, Patient-reported outcomes and health status. Fewer complications indicate a better surgical outcome
Hospital discharge (assessed up to day 14)
VARC-3 Composite clinical end-points
Time Frame: 30-days postoperatively
Valvular Academic Research Consortium V.3.0 clinical endpoints (Mortality, Neurologic events, Hospitalization, Rehospitalization, Bleeding and transfusions, Vascular and access-related complications, Cardiac structural complications, Other procedural or valve-related complications, New conduction disturbances and arrhythmias, New conduction disturbances and arrhythmias, Myocardial infarction, Bioprosthetic valve dysfunction, Leaflet thickening and reduced motion, Clinically significant valve thrombosis, Patient-reported outcomes and health status. Fewer complications indicate a better surgical outcome
30-days postoperatively
Cardiac rehabilitation attendance
Time Frame: 3-months postoperatively
Percent of people attending cardiac rehabilitation
3-months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2023

Primary Completion (Estimated)

March 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

October 26, 2022

First Submitted That Met QC Criteria

November 14, 2022

First Posted (Actual)

November 15, 2022

Study Record Updates

Last Update Posted (Actual)

August 21, 2024

Last Update Submitted That Met QC Criteria

August 19, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NS-NHIG-2021-1905

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on Standard care

Subscribe